What Is Jefferies Saying About Laurus Labs, Colgate and HUL?
Jefferies has released fresh research updates on Laurus Labs, Colgate and Hindustan Unilever (HUL), offering a mix of cautious and optimistic views. While the pharmaceutical segment faces muted prospects in the ARV business, consumer stocks are expected to recover gradually from GST-related disruptions.
Jefferies on Laurus Labs 🧪
Laurus Labs’ performance remains steady in its Contract Development and Manufacturing Organisation (CDMO) segment, particularly in animal health. However, the outlook for antiretroviral (ARV) therapies remains subdued.
| Metric | Value | Notes |
|---|---|---|
| Recommendation | Underperform | Cautious stance |
| Target Price | ₹700 (↑ from ₹590) | Revised upward despite muted growth |
| Capex Plan | US$600 Mn over 8 years | New Vizag site expansion |
| Focus Areas | ADC & CGT Modalities | Signals long investment cycle |
Layman’s View: ARV drugs form part of Laurus’s older portfolio used in HIV treatment. CDMO refers to manufacturing research-driven drugs for other companies. While Laurus’ long-term R&D expansion is promising, the payback may be delayed, hence Jefferies’ ‘Underperform’ tag.
Want to see which stocks could outperform Laurus in pharma momentum? Explore our Nifty Option Tip for expert-curated positional setups this week.
Jefferies on Colgate 🪥
Colgate-Palmolive’s Q2 results were largely in line with Jefferies’ expectations, with temporary disruptions caused by the GST rate cut. Despite soft demand trends, the brokerage retains a positive stance based on brand leadership and premium portfolio growth.
| Parameter | Observation | Implication |
|---|---|---|
| Recommendation | Buy | Long-term value intact |
| Target Price | ₹2,700 | EPS cut by 4–5% |
| Key Factor | GST 2.0 destocking | Short-term volume hit |
| Premium Portfolio | Strong growth | Supports margins |
Layman’s View: EPS (Earnings per Share) measures profit allocated to each share. A 4–5% EPS cut means short-term growth pain, but Jefferies’ buy rating suggests recovery potential once GST-related distortions normalize.
Jefferies on Hindustan Unilever (HUL) 🧴
Jefferies remains bullish on HUL with a raised price target and positive view on new leadership strategy. Short-term headwinds persist due to GST rate adjustments impacting sales and distribution, but medium-term growth visibility remains intact.
| Metric | Details | Notes |
|---|---|---|
| Recommendation | Buy | Positive long-term strategy |
| Target Price | ₹3,050 (↑ from ₹3,000) | Revised higher |
| Key Risk | GST 2.0 impact | Likely to spill over into Q3 |
| Upcoming Event | Ice Cream Business Listing (Q4) | Could unlock value |
Layman’s View: GST rate cuts reduce consumer prices but temporarily hurt distributor margins and company revenue. HUL’s diversified product base and leadership continuity should help navigate near-term pain.
Looking for more data-backed market moves? Follow our expert BankNifty Intraday Tip for tactical setups based on institutional positioning.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, highlights that Jefferies’ updates reflect a cautious optimism — strong consumer names (HUL, Colgate) retain buy ratings despite temporary GST distortions, while pharma names like Laurus face longer gestation returns. Investors should diversify across defensive and growth names rather than chasing short-term volatility. Discover more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Jefferies Reports
- What Does Jefferies Expect From Laurus Labs’ CDMO Expansion?
- Why Did Jefferies Retain a Buy on HUL Despite GST Disruptions?
- How Are Premium FMCG Portfolios Driving Colgate’s Future?
- Should Investors Stay Cautious on ARV-Focused Pharma Companies?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
